Mission Statement, Vision, & Core Values (2026) of Ipsen S.A.

Born in 1929 and now a Paris-based biopharmaceutical force with roughly 5,000 employees, Ipsen S.A. channels a clear, patient-first purpose-improve patients' lives-into a focused strategy delivering innovative medicines across oncology, rare diseases, and neuroscience, with products registered in 88 countries and a direct commercial presence in over 30; guided by a mission to address high unmet medical needs, a vision to be the leading global mid-size biopharma, and core values of integrity, collaboration, innovation, excellence, and patient-centricity, Ipsen leverages a science-led, patient-driven approach, a commitment to diversity and inclusion, and a culture of accountability to build a sustainable, high-value pipeline and deliver measurable impact for patients, caregivers, and society.

Ipsen S.A. (IPN.PA) - Intro

• Founded: 1929 (Henri Beaufour)
• Headquarters: Paris, France
• Employees: approximately 5,000 worldwide
• Products registered in: ~88 countries
• Direct commercial presence in: >30 countries

• Mission: Improve patients' lives by delivering transformative therapies where unmet medical need is highest, with a strong emphasis on quality of life for patients and caregivers.
• Vision: To be a leading global mid‑size biopharmaceutical company concentrating on transformative medicines in oncology, rare diseases and neuroscience.
• Purpose: Prolong lives, improve health outcomes and have measurable societal impact through focused innovation and access.

• Oncology - advancing targeted therapies and combinations to address hard‑to‑treat cancers.
• Rare diseases - developing specialty medicines for rare endocrine, genetic and neuromuscular disorders.
• Neuroscience - improving symptomatic control and functional outcomes for neurological conditions.
• Commercial excellence - expanding access in core markets and selectively entering new geographies with direct operations and partners.

• Patient‑centricity: decisions anchored in patient benefit and caregiver needs.
• Scientific rigor: disciplined R&D and evidence generation to support therapeutic value.
• Collaboration: cross‑functional and external partnerships to accelerate development and access.
• Integrity & accountability: ethical behavior, compliance and measurable commitments.
• Excellence & agility: continuous improvement, operational efficiency and responsiveness.

• Clinical milestones: progression of oncology, rare disease and neuroscience pipelines through Phases II/III and regulatory approvals.
• Commercial metrics: product registrations (88 countries), direct presence (>30 countries), and revenue growth (≈€3.9bn in 2023).
• Societal outcomes: improved patient quality of life and caregiver support through targeted programs and access initiatives.

Ipsen S.A. (IPN.PA) - Overview

• Mission: Improve patients' lives and quality of life for patients and caregivers through innovative medicines that address unmet medical needs.
• Approach: Science-led, patient-driven R&D with the patient experience central to strategy and decision-making.
• Pipeline focus: Specialty care in oncology, rare diseases/endocrinology, and neuroscience with targeted investments to maximize clinical and commercial value.
• People & culture: Attract, retain and develop talent; foster diversity, inclusion and collaboration to drive innovation and operational excellence.

• Bring full potential of innovative medicines to patients via optimized development and launch strategies.
• Build a high-value, sustainable pipeline through selective investing, external partnerships and internal discovery.
• Deliver efficiencies across operations to reallocate resources into priority R&D and commercial programs.
• Promote a culture of collaboration, accountability and continuous development for employees and stakeholders.

• Maximizing patient access through global commercial presence and reimbursement strategies.
• Partnering with academic institutions, biotech companies and patient organizations to accelerate development.
• Embedding patient experience metrics into clinical development and post-marketing activities.

Ipsen S.A. (IPN.PA) - Mission Statement

• Be a global mid‑size biopharma leader delivering transformative therapies in oncology, rare disease and neuroscience.
• Empower every team member to contribute with passion and care to address patients' unmet needs.
• Foster an open, respectful, diverse and inclusive culture that prioritizes employee development and collaborative excellence.
• Create measurable impact for patients, society and the environment through purpose‑driven operations and innovation.

• Diversity & inclusion initiatives with measurable targets for gender balance and leadership representation.
• Continuous learning and development investments tied to career pathways for clinical, commercial and R&D talent.
• Ethics, compliance and patient‑centric standards embedded in global processes and supplier relationships.

Ipsen S.A. (IPN.PA) - Vision Statement

• Integrity: Upholding the highest standards of ethical conduct, compliance and transparency across all markets and functions.
• Collaboration: Fostering cross-functional teamwork and external partnerships with academia, biotech and healthcare systems to maximize impact.
• Innovation: Investing in cutting‑edge R&D and translational science to discover and develop first‑and‑best‑in‑class therapies.
• Excellence: Committing to operational and clinical excellence from drug discovery through commercialization and patient support.
• Patient‑Centricity: Prioritizing patient outcomes, access and quality of care in product development and post‑market support.
• Responsibility: Acting as a responsible corporate citizen with strong governance, environmental and social commitments.

Key metrics that illustrate Ipsen's capacity to pursue this vision (most recent fiscal year, rounded):

How the core values translate into measurable actions and initiatives:

• Integrity - Robust compliance programs, global code of conduct, and regular third‑party audits to reduce regulatory risk and preserve trust.
• Collaboration - Strategic alliances and licensing deals that expand reach; co‑development partnerships that accelerate clinical timelines.
• Innovation - Sustained R&D spend supporting a diversified pipeline (oncology, neuroendocrine tumors, rare diseases) and multiple clinical-stage assets.
• Excellence - Manufacturing quality metrics and regulatory approvals across major markets (EU, US, Asia) supporting reliable supply and market access.
• Patient‑Centricity - Patient support programs, real‑world evidence generation, and outcomes‑based initiatives that improve adherence and access.
• Responsibility - ESG targets including emissions reduction, access initiatives in emerging markets, and governance enhancements tied to executive incentives.

For a deeper dive into Ipsen's recent financial performance and implications for investors, see: Breaking Down Ipsen S.A. Financial Health: Key Insights for Investors